Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/16/2024 | $210.00 | Hold → Buy | Melius | |
9/10/2024 | $160.00 → $173.00 | Market Perform | BMO Capital Markets | |
9/10/2024 | $175.00 | Mkt Perform → Mkt Outperform | JMP Securities | |
8/28/2024 | $63.00 | Overweight | Barclays | |
6/17/2024 | $142.00 → $160.00 | Market Perform | BMO Capital Markets | |
5/3/2024 | $40.00 | Buy | BofA Securities | |
4/18/2024 | Perform | Oppenheimer | ||
3/21/2024 | $150.00 | Overweight | KeyBanc Capital Markets |
6-K - Beamr Imaging Ltd. (0001899005) (Filer)
10-Q - ORACLE CORP (0001341439) (Filer)
8-K - ORACLE CORP (0001341439) (Filer)
Investors with a lot of money to spend have taken a bearish stance on Oracle (NYSE:ORCL). And retail traders should know. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ORCL, it often means somebody knows something is about to happen. Today, Benzinga's options scanner spotted 8 options trades for Oracle. This isn't normal. The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish. Out of all of the options we uncovered, there was 1 put, for a total amount of $31,250, a
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o
Chip stocks, led by Nvidia Corp (NASDAQ:NVDA) and Advanced Micro Devices, Inc (NASDAQ:AMD) saw redemption in Thursday's premarket session after a broader market selloff Wednesday. The stock gave up the gain in the regular session. The Biden administration's advanced semiconductor crusade against China and Presidential candidate Donald Trump's remarks against Taiwan Semiconductor Manufacturing Co (NYSE:TSM) cost the semiconductor sector over $500 billion in stock market value on Wednesday, Reuters reports. Chip stocks got a boost from Taiwan Semiconductor's upbeat quarterly results Thursday, thanks to the AI frenzy. The contract chipmaker reported second-quarter revenue of $20.82 bi
SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh
MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, as well as payment and revenue integrity solutions to the U.S. healthcare industry, announced today its CFO transition plan and named Doug Garis as EVP and CFO, effective August 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731993142/en/Doug Garis named EVP and CFO of MultiPlan (Photo: Business Wire) Jim Head, who has served as EVP and CFO of MultiPlan since November 2021, will transition to a Strategic Advisor role to the Company through the end of the
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
Melius upgraded Oracle from Hold to Buy and set a new price target of $210.00
BMO Capital Markets reiterated coverage of Oracle with a rating of Market Perform and set a new price target of $173.00 from $160.00 previously
JMP Securities upgraded Oracle from Mkt Perform to Mkt Outperform and set a new price target of $175.00
Q1 GAAP Earnings per Share up 20% to $1.03, Non-GAAP Earnings per Share up 17% to $1.39Q1 Total Revenue $13.3 billion, up 7% in USD and up 8% in constant currencyQ1 Total Remaining Performance Obligations up 53% to $99 billionQ1 Cloud Revenue (IaaS plus SaaS) $5.6 billion, up 21% in USD and up 22% in constant currencyQ1 Cloud Infrastructure (IaaS) Revenue $2.2 billion, up 45% in USD and up 46% in constant currencyQ1 Cloud Application (SaaS) Revenue $3.5 billion, up 10% in both USD and constant currencyQ1 Fusion Cloud ERP (SaaS) Revenue $0.9 billion, up 16% in USD and up 17% in constant currencyQ1 NetSuite Cloud ERP (SaaS) Revenue $0.9 billion, up 20% in both USD and constant currencyAUSTIN,
Earnings Results to be released on September 9, 2024, After the Close of the Market AUSTIN, Texas, Sept. 3, 2024 /PRNewswire/ -- Oracle Corporation today announced that its first quarter fiscal year 2025 results will be released on Monday, September 9th, after the close of the market. Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results. The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor. About Oracle Oracle offers integrated suites of applications plus secure, auton
Q4 Total Remaining Performance Obligations up 44% to $98 billionQ4 GAAP Earnings per Share $1.11, Non-GAAP Earnings per Share $1.63Q4 Total Revenue $14.3 billion, up 3% in USD, up 4% in constant currency Q4 Cloud Revenue (IaaS plus SaaS) $5.3 billion, up 20% in USD and constant currencyQ4 Cloud Infrastructure (IaaS) Revenue $2.0 billion, up 42% in USD and constant currency Q4 Cloud Application (SaaS) Revenue $3.3 billion, up 10% in USD and constant currencyQ4 Fusion Cloud ERP (SaaS) Revenue $0.8 billion, up 14% in USD and constant currencyQ4 NetSuite Cloud ERP (SaaS) Revenue $0.8 billion, up 19% in USD and constant currencyFY 2024 Total Revenue $53.0 billion, up 6% in USD and constant curren
SC 13D/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G - Beamr Imaging Ltd. (0001899005) (Subject)
4 - ORACLE CORP (0001341439) (Issuer)
4 - ORACLE CORP (0001341439) (Issuer)
4 - ORACLE CORP (0001341439) (Issuer)
Oracle Health delivers free code to enable organizations to securely access a Veteran's health history to help ensure timely and accurate treatment no matter where care is received AUSTIN, Texas, Sept. 17, 2024 /PRNewswire/ -- Oracle Health today released new code that will enable its customers to support the Veteran Interoperability Pledge. A framework that allows US Department of Veterans Affairs (VA) and community providers to securely share patient health information, the Pledge supports the care of Veterans receiving treatment both inside and outside the VA network. With the new code, customers can seamlessly integrate APIs from the VA into Oracle Health's electronic health record (EHR)
New release delivers 12 JDK Enhancement Proposals that help developers increase productivity by improving the Java language Enhancements to the platform's performance, stability, and security help organizations accelerate business growth Java Management Service 9.0 and Graal JIT Compiler help organizations manage Java applications and improve peak performance AUSTIN, Texas, Sept. 17, 2024 /PRNewswire/ -- Oracle today announced the availability of Java 23, the latest version of the world's number one programming language and development platform. Java 23 (Oracle JDK 23) delivers thousands of improvements to help developers increase productivity and drive innovation, while enhancements to th
Financial Crime and Compliance Management Monitor delivers advanced visualizations to support banks in managing risk and meeting compliance analysis and reporting requirements AUSTIN, Texas, Sept. 17, 2024 /PRNewswire/ -- Oracle today announced Oracle Financial Crime and Compliance (FCCM) Management Monitor Cloud Service. With the new solution banks, fintechs, and other financial services companies can gain a holistic, centralized view of their FCCM efforts, enabling them to identify potential issues faster and, proactively manage risk to thwart criminal activity and reduce compliance costs. With its granular reporting capabilities, the system also helps banks demonstrate effective FCCM effo